Table A1.
Studies about lung cancer harboring rare EGFR mutations.
| Author, Year | N † | EGFR TKIs | Categories of Mutation Types | Response Rate (%) | Median PFS (months) | Median OS (months) |
|---|---|---|---|---|---|---|
| Kobayasi, et al., 2013 | 8 | Erlotinib | Compound mutations (sensitive mutation with other mutation): | |||
| G719X with others (n = 3) | 100% | |||||
| L858R with others (n = 3) | 66.7% | |||||
| L861Q + E709A (n = 1) | 100% | |||||
| delL747_T751+R776S (n = 1) | 100% | |||||
| Chiu, et al., 2015 | 151 | Erlotinib, Gefitinib | Uncommon mutation (G719X, L861Q, S768I, G719X + L861Q, and G719X + S768I) |
41.6% | 7.7 | 24.0 |
| Common mutation | 66.5% | 11.4 | 29.7 | |||
| Peng, et al., 2015 | 6 | Gefitinib | L858R compound mutations | 16.7% | 12.2 | 28.6 |
| Yang, et al., 2015 | 75 | Afatinib | Group 1: point mutations and duplications in exons 18-21(L861G, G719X, S768I, and other point mutations alone or in combination with each other) | 71.1% | 10.7 | 19.4 |
| Group 2: de-novo T790M mutation in exon 20 (alone or in combination with other mutations) | 14.3% | 2.9 | 14.9 | |||
| Group 3: exon 20 insertions | 8.7% | 2.7 | 9.2 | |||
| Chen, et al., 2017 | 66 | Icotinib, Gefitinib, Erlotinib, Afatinib | Group 1: sensitizing rare mutations (G719X, L861Q, S768I) | 32.4% | 4.1 | |
| Group 2: resistant mutation (exon 20 insertion) | 11.1% | 3.1 | ||||
| Group 3: complex mutation (L858R + T790M) | 30% | 8.6 | ||||
| Kauffmann-Guerrero, et al., 2017 | 12 | Erlotinib, Afatinib | Rare mutation | 28.5 | ||
| Complex mutation | 20% | |||||
| Tu, et al., 2018 | 62 | EGFR TKIs | G719X | 50% | 11.6 | 25.2 |
| Exon 20 insertion | 0% | 3 | 12.5 | |||
| T790M | 0% | 1 | 2.4 | |||
| Complex L858R | 75% | 15.2 | 27.7 | |||
| Others | 10% | 2.9 | 11.7 | |||
| Shen, et al., 2018 | 56 | Gefitinib, Erlotinib, Afatinib | Group 1: exon 20 insertions (except A763_Y764 insFQEA) | 20% | ||
| Group 2: non-classical mutations with Del19 or L858R | 58.8% | |||||
| Group 3: non-classical mutations without a combination of Del19 or L858R | 58.8% |
Abbreviation: EGFR = epidermal growth factor receptor; TKI = tyrosine kinase inhibitor; PR = partial response. † Case number of the patients receiving an EGFR TKI.